Open AccessDesigning and Development of a Tandem Bivalent Nanobody against VEGF165
Author(s) -
Farnaz Khodabakhsh,
Morteza Salimian,
Pardis Ziaee,
Fatemeh KazemiLomedasht,
Mahdi Behdani,
Reza Ahangari Cohan
Publication year - 2021
Publication title -
avicenna journal of medical biotechnology.
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.399
H-Index - 22
eISSN - 2008-4625
pISSN - 2008-2835
DOI - 10.18502/ajmb.v13i2.5519
Subject(s) - bivalent (engine) , microbiology and biotechnology , chemistry , tandem , tandem repeat , monoclonal antibody , antibody , western blot , in vivo , biochemistry , biology , materials science , metal , organic chemistry , genome , gene , immunology , composite material
Inhibition of angiogenesis using monoclonal antibodies is an effective strategy in cancer therapy. However, they could not penetrate sufficiently into solid tumors. Antibody fragments have solved this issue. However, they suffer from short in vivo half-life. In the current study, a tandem bivalent strategy was used to enhance the pharmacokinetic parameters of an anti-VEGF165 nanobody.